Skip to content

Independent register of U.S. FDA drug recalls · updated Oct 10, 2026

Is Morphine recalled?

Yes — there is an active recall. 7 ongoing FDA recalls mention Morphine (189 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Morphine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Morphine recalls on record

none so far in 2026; 189 on record, newest first

Jun 2, 2015 Class II · Moderate risk

Morphine 30 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1736-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 60 mg/ml + Fentanyl 12

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1713-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 20

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1712-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Ropivacaine 5 mg/ml +Baclofen 20 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1711-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 3

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1710-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 3

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1709-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 2

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1708-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 10

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1707-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Fentanyl 1

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1706-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Clonidine 750 mcg/ml + Baclofen 15 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1705-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Clonidine 500 mcg/ml +Bupivacaine 2.5 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1704-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 45 mg/ml + Bupivacaine 8 mg/ml + Baclofen 25 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1703-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 25 mg/ml + Bupivacaine 30 mg/ml + Clonidine 200 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1702-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 25 mg/ml + Bupivacaine 20 mg/ml + Clonidine 2

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1701-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 70 mg/ml + Clonidine 1

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1615-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 70 mg/ml + Bupivacaine 40 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1614-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 64 mg/ml + Bupivacaine 10 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1613-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 60 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1612-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml +Fentanyl 1

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1611-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Clonidine 200 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1610-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Clonidine 100 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1609-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml + Bupivacaine 2.5 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1608-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 50 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1607-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 45 mg/ml + Bupivacaine 40 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1606-2015

Jun 2, 2015 Class II · Moderate risk

Morphine 45 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1605-2015